| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a clinical-stage biotechnology company with a core focus on discovering and commercializing novel pharmaceutical solutions for cardiometabolic disorders. Its leading investigational drug, DA-1241, a unique G-Protein-Coupled Receptor 119 agonist, is currently undergoing Phase 2a clinical trials for metabolic dysfunction-associated steatohepatitis (MASH). This follows the successful completion of Phase 1 trials for type 2 diabetes mellitus (T2DM), and the compound holds promise …
Over the last 12 months, insiders at MetaVia Inc. have bought $0 and sold $0 worth of MetaVia Inc. stock.
On average, over the past 5 years, insiders at MetaVia Inc. have bought $3.31M and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 14,200 shares for transaction amount of $9,940 was made by Woodworth Marshall H (Chief Financial Officer) on 2025‑06‑04.
| 2025-06-04 | Woodworth Marshall H | Chief Financial Officer | 14,200 0.0543% | $0.70 | $9,940 | -5.82% | ||
| 2025-05-08 | DONG-A ST CO., LTD | 10 percent owner | 4.65M 18.0257% | $0.71 | $3.3M | -5.51% |
| DONG-A ST CO., LTD | 10 percent owner | 9995679 151.7232% | $12.59M | 1 | 0 | <0.0001% |
| Woodworth Marshall H | Chief Financial Officer | 44279 0.6721% | $55,791.54 | 1 | 0 | <0.0001% |
$13,664,154 | 40 | -70.35% | $7.05M | |
$812,698 | 12 | -57.09% | $7.89M | |
$4,146,041 | 11 | -40.86% | $8.55M | |
$120,379 | 10 | -24.48% | $7.65M | |
$176,752 | 10 | -28.86% | $6.66M |
| Increased Positions | 8 | +40% | 21,510 | +52.37% |
| Decreased Positions | 9 | -45% | 26,243 | -63.9% |
| New Positions | 4 | New | 14,076 | New |
| Sold Out Positions | 8 | Sold Out | 25,765 | Sold Out |
| Total Postitions | 19 | -5% | 36,338 | -11.52% |